The potential role of appetite in predicting weight changes during treatment with olanzapine

Case, Michael; Treuer, Tamas; Karagianis, Jamie; Hoffmann, Vicki Poole
January 2010
BMC Psychiatry;2010, Vol. 10, p72
Academic Journal
Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite. Methods: Data were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4). Results: In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change. Conclusions: Early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales. Clinical Trials Registration: This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at http://clinicaltrials.gov/ct2/home, under NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.


Related Articles

  • Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation. Fernø, Johan; Varela, Luis; Skrede, Silje; Vázquez, María Jesús; Nogueiras, Rubén; Diéguez, Carlos; Vidal-Puig, Antonio; Steen, Vidar M.; López, Miguel // PLoS ONE;2011, Vol. 6 Issue 6, p1 

    The success of antipsychotic drug treatment in patients with schizophrenia is limited by the propensity of these drugs to induce hyperphagia, weight gain and other metabolic disturbances, particularly evident for olanzapine and clozapine. However, the molecular mechanisms involved in...

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • Sleep deprivation can put on the pounds.  // Consumer Reports on Health;Apr2005, Vol. 17 Issue 4, p7 

    The article reports that lack of sleep may encourage weight gain by intensifying your appetite. In a study of more than 900 people reported in January 2005, researchers at Eastern Virginia Medical School found that the less people slept each night, the more likely they were to be overweight. An...

  • Fat Mass- and Obesity-Associated (FTO) Gene and Antipsychotic-Induced Weight Gain: An Association Study. Shing, Emily C.; Tiwari, arun K.; Brandl, Eva J.; Zai, Clement C.; Lieberman, Jeffrey a.; Meltzer, Herbert Y.; Kennedy, James L.; Müller, Daniel J. // Neuropsychobiology;Feb2014, Vol. 69 Issue 1, p59 

    Objectives: Genetic variation in the fat mass- and obesity-associated gene (FTO) has been associated with obesity in the general population. In this study we have investigated these variants for association with antipsychotic-induced weight gain (AIWG). Methods: A total of 218 patients with...

  • Olanzapine in the Treatment of Behavioral Problems Associated with Autism: An Open-Label Trial in Kuwait. Fido, Abdullahi; Al-Saad, Samira // Medical Principles & Practice;Sep2008, Vol. 17 Issue 5, p415 

    Objectives: To study the efficacy and safety of olanzapine for the treatment of children with autism associated with disruptive behavior problems. Subjects and Methods: A prospective open-label trial was conducted on 40 male children (mean age 12.2 ± 2.2 years, range 7–17 years)...

  • Acute Peripheral but Not Central Administration of Olanzapine Induces Hyperglycemia Associated with Hepatic and Extra-Hepatic Insulin Resistance. Girault, Elodie M.; Alkemade, Anneke; Foppen, Ewout; Ackermans, Mariëtte T.; Fliers, Eric; Kalsbeek, Andries; Bader, Michael // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Atypical antipsychotic drugs such as Olanzapine induce weight gain and metabolic changes associated with the development of type 2 diabetes. The mechanisms underlying the metabolic side-effects of these centrally acting drugs are still unknown to a large extent. We compared the effects of...

  • Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats. Hu, Yueshan; Young, Alan J.; Ehli, Erik A.; Nowotny, Dustin; Davies, Paige S.; Droke, Elizabeth A.; Soundy, Timothy J.; Davies, Gareth E. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Olanzapine is a first line medication for the treatment of schizophrenia, but it is also one of the atypical antipsychotics carrying the highest risk of weight gain. Metformin was reported to produce significant attenuation of antipsychotic-induced weight gain in patients, while the study of...

  • Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment. Lian, Jiamei; Huang, Xu-Feng; Pai, Nagesh; Deng, Chao // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic...

  • The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. Morgan, Andrew P.; Crowley, James J.; Nonneman, Randal J.; Quackenbush, Corey R.; Miller, Cheryl N.; Ryan, Allison K.; Bogue, Molly A.; Paredes, Sur Herrera; Yourstone, Scott; Carroll, Ian M.; Kawula, Thomas H.; Bower, Maureen A.; Sartor, R. Balfour; Sullivan, Patrick F. // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    The second-generation antipsychotic olanzapine is effective in reducing psychotic symptoms but can cause extreme weight gain in human patients. We investigated the role of the gut microbiota in this adverse drug effect using a mouse model. First, we used germ-free C57BL/6J mice to demonstrate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics